

Relationships of Subunits of Type-1 Serine/Threonine Protein Phosphatase to Morphology and Aggregation of B Cells¹

Norio Takizawa,* Masakazu Komatsu,* Yusuke Mizuno,*² Takeshi Kawamura,* Masaki Ito,¹ Takeshi Nakano,¹ and Kunimi Kikuchi*³

*Section of Biochemistry, Institute of Immunological Science, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, Hokkaido 060; and ¹The First Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie 514

Received for publication, April 21, 1997

To elucidate the roles of serine/threonine protein phosphatases PP1 and PP2A in the morphological changes of B-lymphocytes during development and in immune responses, we investigated alterations of protein levels of catalytic subunits of PP1 and PP2A and regulatory subunits of PP1 including M130/M133, inhibitor-1 (I-1) and inhibitor-2 (I-2) in B-cell lines at different maturational stages and during their aggregation induced by phorbol myristate acetate (PMA). The protein levels of PP1 δ and/or M130/M133 were significantly lower in B-cell lines without pseudopods, WEHI-231, BAL-17, Daudi, and CESS, than in those with pseudopods, Bcl.1, A20, M12, and SKW6.4, whereas the amounts of PP1 α and PP2A were similar among them. During aggregation of A20 and CESS cells induced by PMA, an activator of PKC, the amount of PP1 δ was progressively decreased, and this decrease was blocked by H7, an inhibitor of PKC. The amount of PP1 α was constant under these conditions. Okadaic acid, an inhibitor of PP1 and PP2A, also induced aggregation of A20 cells at concentrations sufficient to inhibit PP1, but not at lower concentrations that inhibit PP2A alone. These results suggest that myosin light chain phosphatase composed of PP1 δ and M130/M133 is involved in the maintenance and regulation of cytoskeletal structures in B-lymphocytes.

Key words: aggregation, B cell, morphology, PP1, protein phosphatase.

Protein phosphorylation and dephosphorylation are crucial mechanisms for regulation of a variety of biological events, such as activation, apoptosis, and differentiation of T- and B-lymphocytes. Morphological changes accompanying these biological events are regulated by reversible phosphorylation of cytoskeletal components such as ezrin (1) and paxillin (2). Hence, protein phosphatases are thought to play important roles in morphological alterations of lymphocytes in various immune responses and in development of the immune system (3, 4).

In this study, we examined protein levels of serine/threonine protein phosphatases PP1 and PP2A in various murine and human B-cell lines at different maturational stages and during aggregation of B-cells induced by PMA, a PKC activator (5), or by okadaic acid, a protein phosphatase inhibitor (6, 7).

Mammals have at least four isoforms of PP1 catalytic subunits, termed PP1 α , PP1 γ 1, PP1 γ 2, and PP1 δ (also

called PP1 β). Each catalytic subunit is associated with inhibitor-1 (I-1), inhibitor-2 (I-2), NIPP-1, G-component, or M130/M133. PP1 is thought to be located in nuclei in a form complexed with NIPP-1, and at myofibrils in a form complexed with M130/M133 (8-10). These isoforms of PP1 show characteristic patterns of tissue distribution (11, 12), but their distinctive functions are not well understood.

We have reported a selective elevation in amount of PP1 α in rat ascites hepatomas, suggesting that PP1 α is involved in malignant phenotypes and/or high proliferating rates (13-15). We have also reported that amounts of PP1 α were progressively decreased in livers of non-obese diabetic mice (IDDM model mice) as a function of increasing concentrations of blood glucose, whereas the amounts of PP1 γ 1 and PP1 δ were unchanged (12). These previous results suggest that the isoforms of PP1 have different roles and regulatory mechanisms. Recently, it was reported that PP1M, a holoenzyme of PP1 located at myofibrils, is composed of PP1 δ and M130/M133 (16).

It is well-known that B-lymphocytes during development show morphological alterations accompanied with expression of various specific cell-surface markers, and that B-cells morphologically change in response to extracellular stimuli (17). To elucidate the roles of protein phosphatases in these immunological events, we have examined the correlation of protein levels of PP1 and PP2A with morphological features in various B-cell lines at different maturational stages and their alterations during aggrega-

¹ This work was supported in part by Grants-in-Aid for Scientific Research on Priority Areas provided by the Ministry of Education, Science, Sports and Culture of Japan.

² Present address: Department of Food Science and Human Nutrition, Faculty of Human Ecology, Fuji Women's College, Hanakawa Minami 4-5, Ishikari, Hokkaido 061-32.

³ To whom correspondence should be addressed. Tel/Fax: +81-11-707-6839, E-mail: kikuchi@imm.hokudai.ac.jp

Abbreviations: PP1, protein phosphatase 1; PKC, protein kinase C; PMA, Phorbol 12-myristate 13-acetate; OA, okadaic acid; H7, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride.

tion induced by PMA or okadaic acid.

MATERIALS AND METHODS

Materials—The rabbit anti-PP1 antibodies were prepared as described (12). The rabbit anti-PP2A antibody, which recognizes both PP2A α and PP2A β , was obtained from UBI (Lake Placid, NY). The rabbit anti-M130/M133 antibody was prepared as described (18, 19). The rabbit anti-I-2 antibody which recognizes human I-2 was prepared as described (20, 21). The rabbit anti-I-1 antibody was prepared as described (22). Myosin light chain phosphatase, MLCP, was prepared as described (23, 24). Okadaic acid (OA) and phorbol 12-myristate 13-acetate (PMA) were obtained from Wako Pure Chemical Industries (Osaka). The protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) was from Seikagaku (Tokyo).

Cell Culture—The human B cell lines, Daudi (25), SKW6.4 (26), and CESS (27), were maintained in RPMI 1640 medium (GIBCO-BRL) supplemented with 2 mg/ml NaHCO₃, pH 7.2, 10% heat-inactivated fetal calf serum (FCS), and 2 mM L-glutamine, at 37°C in an atmosphere containing 5% CO₂. The murine B cell lines, WEHI-231 (28), Bcl.1 (29), BAL-17 (30), A20 (30), and M12 (30), were maintained in the human culture medium plus 50 μ M 2-mercaptoethanol (2-ME).

Stimulation with PMA—Logarithmically growing A20 cells that adhered to the plate bottom (NIPRO, nontreated plate) were stimulated with various concentrations of PMA in a CO₂ incubator for 24 h. Logarithmically growing CESS cells were resuspended at 1×10^6 cells/ml in the culture medium, and then stimulated with 50 ng/ml PMA with or without 40 μ M H7. After appropriate incubation in a CO₂ incubator, the culture was stopped with ice-cold 150 mM NaCl.

Preparation of Cell Extracts from B Cells—Cells (2×10^7) from logarithmically growing cultures were collected by centrifugation at $400 \times g$ for 5 min, and washed with ice-cold 150 mM NaCl. The cell pellets were lysed by the addition of extraction buffer (200 μ l) containing 50 mM Tris-HCl, pH 7.4, 250 mM sucrose, 2 mM EDTA, 2 mM EGTA, 0.1 mM PMSF, 0.1 mM TPCK, 0.5 mM benzamide, 1 μ M leupeptin, and 1.0% Nonidet P-40 (NP-40). The lysates were centrifuged at $8,000 \times g$ for 20 min at 4°C and the resulting supernatants were used as extracts.

Western Blot Analysis—Proteins (70 μ g) of the extract were separated on a 12% SDS-PAGE gel under reducing conditions and electrophoretically transferred to a nitrocellulose membrane. The blot was blocked with skim milk, incubated for 3 h with the rabbit anti-protein phosphatase antibodies, washed with phosphate-buffered saline containing 0.1% Tween-20, and then incubated with 1 μ g/ml horseradish peroxidase-labeled donkey anti-rabbit IgG antibody (Chemicon, Temecula, CA) for 1 h. Immunoreactive bands were detected with an ECL Western blotting detection kit (Amersham International plc, England).

RESULTS

Western Blot Analysis of PP1 and PP2A in Various Human and Murine B-Cell Lines—To examine the roles of serine/threonine protein phosphatases PP1 and PP2A in

B-cells, we analyzed by Western blotting the amounts of catalytic subunits of PP1 and PP2A and regulatory subunits of PP1 including M130/M133, I-1, and I-2, in various murine and human B-cell lines.

In 5 murine cell lines, WEHI-231, Bcl.1, BAL-17, A20, and M12, the amounts of PP1 α were at similar levels. PP1 γ 1, PP1 γ 2, and I-1 were undetectable in all the cell lines examined under similar conditions. In contrast, as shown in Fig. 1, PP1 δ and M130/M133 showed a variety of levels, dependent on the cell lines. When compared with WEHI-231, a cell line at the earliest stage of maturation among the 5 cell lines, relative amounts of PP1 δ in Bcl.1, BAL-17, A20, and M12 were 0.29, 1.14, 0.57, and 0.75, respectively, those of M130/M133 were 0.51, 0.95, 0.71, and 0.32, respectively, and those of PP2A were 1.20, 1.00, 1.20, and 1.20, respectively (Fig. 1A).

In 3 human cell lines, Daudi, SKW6.4, and CESS, amounts of PP1 α were at similar levels. PP1 γ 1, PP1 γ 2, and I-1 were undetectable. However, the amounts of PP1 δ and M130/M133 were 0.59 and 0.67 in SKW6.4, and 0.41 and 1.2 in CESS, respectively, when compared with those in Daudi (Fig. 1B). The amounts of I-2 and PP2A were 0.73 and 1.00 in SKW6.4 and 0.27 and 0.80 in CESS, compared with those in Daudi. Figure 2 shows the morphology of the B-cell lines examined. WEHI-231 and BAL-17 of the murine cell lines, and Daudi and CESS of the human cell lines were round without pseudopods. In contrast, murine Bcl.1, A20, M12, and human SKW6.4 possessed pseudopods. It should be noted that the protein levels of PP1 δ and/or M130/M133 were relatively lower in the cells with pseudopods than in the cells without pseudopods. Taking into account that myosin light chain phosphatase, MLCP, is a holoenzyme form composed of PP1 δ and M130/M133, the difference in amounts of PP1 δ and/or M130/M133 may reflect the characteristic morphology of the B-cell lines examined.

Effect of Incubation with PMA on PP1 and PP2A—Previously, it was reported that in response to incubation with okadaic acid, platelets showed formation of pseudopods. Phorbol ester is known to induce aggregation of




Fig. 1. Western blot analysis of PP1 and PP2A in various human and murine B-cell lines. Murine (A) and human (B) cell extracts (70 μ g protein) were subjected to SDS-PAGE followed by transfer to a nitrocellulose membrane. Western blot analysis was carried out by using antibodies against PP1 α (a), PP1 δ (b), M130/M133 (c), PP2A (d), and I-2 (e). (A) Lanes: 1, WEHI-231; 2, Bcl.1; 3, BAL-17; 4, A20; 5, M12. (B) lanes: 1, Daudi; 2, SKW6.4; 3, CESS.




Fig. 2. Morphology of human and murine B-cell lines. Cells (2×10^5 cells/ml) were incubated for 48 h in culture medium. Panels: A, WEHI-231; B, Bcl.1; C, BAL-17; D, A20; E, M12; F, Daudi; G, SKW6.4; H, CESS.

platelets. Myosin light chain serves to maintain the morphology of cells, and myosin light chain phosphatase composed of PP1 δ and M130/M133 is thought to be involved in the maintenance of cellular structure through dephosphorylation of myosin light chain. Hence we examined effects of incubation with PMA on aggregation of various B-cell lines. Of the 6 cell lines, WEHI-231, Bcl.1, A20, M12, SKW6.4, and CESS, only A20 and CESS aggregated in response to incubation with 50 ng/ml PMA.

As shown in Fig. 3, the aggregation of A20 cells at 24 h of incubation became more marked with increasing concentrations of PMA. As shown in Fig. 4, under these conditions, the amounts of PP1 δ and M130/M133 were decreased to 0.50 and 0.71 of the controls, respectively, whereas that of PP1 α remained constant. Figure 5 shows the aggregation of CESS cells in response to incubation with 50 ng/ml PMA. The amounts of PP1 δ and M130/M133 were decreased to 0.48 and 0.70, respectively, of the controls after 12-h




Fig. 4. Effects of incubation with PMA on PP1 and PP2A in A20 cells. Cells were incubated for 24 h with various concentrations of PMA. Cell extracts (70 μg protein) were subjected to SDS-PAGE followed by transfer to a nitrocellulose membrane. Western blot analysis was carried out by using antibodies against PP1 α (a), PP1 δ (b), and M130/M133 (c). Lane 1, myosin light chain phosphatase (0.2 μg); lanes 2-6, cells incubated without (lane 2) or with 0.8 ng/ml (lane 3), 8 ng/ml (lane 4), 80 ng/ml (lane 5), and 800 ng/ml (lane 6) PMA.

Fig. 3. Aggregation of A20 cells with PMA. Cells were incubated for 24 h with various concentrations of PMA. Panels: A, none; B, 0.8 ng/ml; C, 8.0 ng/ml; D, 80 ng/ml; E, 800 ng/ml.

incubation, but under identical conditions, the amounts of PP1 α , PP2A, and I-2 were at the control levels (Fig. 6). As shown in Fig. 7 and Fig. 8, 40 μM H7, a PKC inhibitor, blocked the PMA-induced aggregation of CESS cells at 24 h, as well as the decrease in amount of PP1 δ with PMA, 55%, and with PMA plus H7, 77% of the control.

Effects of Okadaic Acid on Aggregation of A20 Cells— We examined the effects of okadaic acid on aggregation of A20 cells. During incubation of A20 cells with various concentrations of okadaic acid for 24 h in the absence or presence of 8 ng/ml PMA, 1 nM okadaic acid showed no effect on aggregation, irrespective of the presence of PMA, but at concentrations higher than 10 nM it increased the aggregation (Fig. 9). CESS cells did not show any aggregation up to 10 ng/ml okadaic acid, and died *via* an apoptotic process on incubation with 50 ng/ml okadaic acid (data not shown). From these results, it was concluded that cell aggregation was induced by okadaic acid at concentrations sufficiently high to inhibit both PP1 and PP2A, but not at low concentrations that inhibit PP2A alone (31).

DISCUSSION

In the present study, we have measured the protein levels of catalytic subunits of PP1 and PP2A and regulatory subunits of PP1 including M130/M133, I-1, and I-2 by Western blotting in 5 murine and 3 human B-cell lines and examined their changes during aggregation induced by an activator of PKC, PMA, or an inhibitor of PP1 and PP2A, okadaic acid. However, PP1 γ 1, PP1 γ 2, or I-1 was not detected in any of the 8 cell lines examined. The amounts of PP1 α and PP2A were at similar levels among the 8 B-cell lines, whereas the amounts of PP1 δ and M130/M133 showed a variety of levels. The B-cell lines used in the




Fig. 5. Aggregation of CESS cells with PMA. Cells were incubated for 6 h without (panel A), with 0.4% DMSO (panel B), or with 0.4% DMSO plus 50 ng/ml PMA (panel C).




Fig. 6. Effects of incubation with PMA on PP1 and PP2A in CESS cells. Cells were incubated with or without 50 ng/ml PMA for various times. Lanes: 1, 0 h; 2, 6 h without PMA; 3, 6 h with PMA; 4, 12 h without PMA; 5, 12 h with PMA. Cell extracts (70 μ g protein) were subjected to SDS-PAGE followed by transfer to a nitrocellulose membrane. Western blot analysis was carried out by using antibodies against PP1 α (a), PP1 δ (b), M130/M133 (c), PP2A (d), and I-2 (e).




Fig. 7. Effects of H7 on aggregation of CESS cells induced with PMA. Cells were incubated for 24 h without (A), with 50 ng/ml PMA (B), or with 50 ng/ml PMA plus 40 μ M H7 (C).

present study express different surface markers, demonstrating that they are frozen at different maturational stages during B-cell development (32). Of the 8 B-cell lines used, WEHI-231 expresses the earliest surface markers (28), and BAL-17 and Bcl.1 express mature markers such

as IgM (29, 30). A20 cells represent the intermediate markers. Bcl.1 can be activated by LPS to secrete IgM (33). M12 lacks the ability to express surface Ig (30). SKW6.4 is an Epstein-Barr virus (EB virus)-positive clone of Daudi (26). SKW6.4 and CESS respond to IL-6 by increasing the




Fig. 8. Effects of H7 on the suppression of PP1 and PP2A with PMA in CESS cells. Cells were incubated without (lane 1), with 50 ng/ml PMA (lane 2), or with 50 ng/ml PMA plus 40 μ M H7 (lane 3). Cell extracts (70 μ g protein) were subjected to SDS-PAGE followed by transfer to a nitrocellulose membrane. Western blot analysis was carried out by using antibodies against PP1 α (a), PP1 δ (b), M130/M133 (c), and PP2A (d).

number of IgM- and IgG-secreting cells (34, 35). These B-cell lines showed a variety of morphological features (Fig. 2). WEHI-231, BAL-17, Daudi and CESS cells were round and did not possess any pseudopod, whereas Bcl.1, A20, M12, and SKW6.4 possessed pseudopods of various shapes. It should be noted that the protein levels of PP1 δ and M130/M133 in the B-cells with pseudopods were specifically lower than those in the B-cells without pseudopods. In thrombin-activated platelets, both of two potent inhibitors of PP1 and PP2A, okadaic acid and calyculin A, were previously reported to induce extremely long pseudopods which contained an array of microtubules and actin filaments (36). Taking these previous results into account, our present data suggest that PP1 δ and M130/M133 are involved in the formation of pseudopods.

The aggregation and adhesion are thought to be due to activation of LFA-1, a lymphocyte integrin (37). Recently, it was reported that Rho is positively involved in the PMA-induced aggregation of JY cells, a B-lymphoblastoid cell line (38). Rho is thought to exert this action by increasing phosphorylation of 20 kDa myosin light chain, MLC (39). Conversely, the exotoxin C3 caused *in situ* ADP ribosylation of Rho (40, 41) and inactivated it, resulting in a block of the PMA-induced cell aggregation (42). It was also reported that GTP γ S enhances Ca²⁺-induced, wortmannin-sensitive phosphorylation of MLC through inhibition of its dephosphorylation. The exotoxin C3 completely abolished the effects of GTP γ S. These results indicated that Rho is positively involved in the GTP γ S-induced phosphorylation of MLC (43). Myosin light chain phosphatase, MLCP, is composed of PP1 δ and M130/M133 and is involved in regulation of phosphorylation of MLC (16). Our present results demonstrate that PP1 δ and M130/M133 are specifically decreased during aggregation of B-cells induced by PMA and that okadaic acid at sufficiently high concentration to inhibit PP1 activity induces cell aggregation. Taken together, our results strongly suggest that PP1 δ and M130/M133 are involved in the regulation of pseudopod formation and aggregation of B-cells, both accompanied with re-organization of microtubules and actin filaments.




Fig. 9. Effects of okadaic acid on aggregation of A20 cells. A20 cells were stimulated by various concentrations of OA without (1) or with (2) 8 ng/ml PMA. Panels: A, 0 ng/ml OA; B, 1 ng/ml OA; C, 10 ng/ml OA; D, 50 ng/ml OA.

The authors thank Mrs. Eiko Yoshida for her skillful assistance.

REFERENCES

1. Egerton, M., Burgess, W.H., Chen, D., Druker, B.J., Bretscher, A., and Samelson, L.E. (1992) Identification of ezrin as 81-kDa tyrosine-phosphorylated protein in T cells. *J. Immunol.* **149**, 1847-1852
2. Melamed, I., Turner, C.E., Aktories, K., Kaplan, D.R., and Gelfand, E.W. (1995) Nerve growth factor triggers microfilament assembly and paxillin phosphorylation in human B lymphocytes. *J. Exp. Med.* **181**, 1071-1079
3. Hathcock, K.S., Hirano, H., and Hodes, R.J. (1993) CD45 expression by murine B cells and T cells: alteration of CD45 isoforms in subpopulations of activated B cells. *Immunol. Res.* **12**, 21-36
4. Arendt, C.W., Hsi, G., and Ostergaard, H.L. (1995) Immobilized antibodies to CD45 induce rapid morphologic changes and increased tyrosine phosphorylation of p56lck-associated proteins in T cells. *J. Immunol.* **155**, 5095-5103
5. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. (1982) Direct activation of calcium-activated phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J. Biol. Chem.* **257**, 7847-7851
6. Fujiki, H., Suganuma, M., Suguri, H., Yoshizawa, S., Takagi, K., Uda, N., Wakamatsu, K., Yamada, K., Murata, M., Yasumoto, T., and Sugimura, T. (1988) Diarrhetic shellfish toxin, dinophysistoxin-1, is a potent tumor promoter on mouse skin. *Jpn. J.*

- Cancer. Res.* **79**, 1089-1093
7. Sugauma, M., Fujiki, H., Suguri, H., Yoshizawa, S., Hirota, M., Nakayasu, M., Ojika, M., Wakamatsu, K., Yamada, K., and Sugimura, T. (1988) Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. *Proc. Natl. Acad. Sci. USA* **85**, 1768-1771
 8. Bollen, M. and Stalmans, W. (1992) The structure, role, and regulation of type 1 protein phosphatases. *Crit. Rev. Biochem. Mol. Biol.* **27**, 227-281
 9. Walter, G. and Mumby, M. (1993) Protein serine/threonine phosphatases and cell transformation. *Biochim. Biophys. Acta* **1155**, 207-226
 10. Sasaki, K., Shima, H., Kitagawa, Y., Irino, S., Sugimura, T., and Nagao, M. (1990) Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1 α gene in rat hepatocellular carcinomas. *Jpn. J. Cancer Res.* **81**, 1272-1280
 11. Shima, H., Hatano, Y., Chun, Y., Sugimura, T., Zhang, Z., Lee, E.Y.C., and Nagao, M. (1993) Identification of PP1 catalytic subunit isotypes PP1 γ 1, PP1 δ , and PP1 α in various rat tissues. *Biochem. Biophys. Res. Commun.* **192**, 1289-1296
 12. Takizawa, N., Mizuno, Y., Ito, Y., and Kikuchi, K. (1994) Tissue distribution of isoforms of type-1 protein phosphatase PP1 in mouse tissues and its diabetic alterations. *J. Biochem.* **116**, 411-415
 13. Kikuchi, K., Mizuno, Y., Kitamura, K., Kakinoki, Y., Nakamura, K., Matsuzawa, S., and Saadat, M. (1993) Expressions and activities of protein phosphatases during carcinogenesis, regeneration, and cell cycle. *Adv. Protein Phosphatases* **7**, 221-236
 14. Takizawa, N., Mizuno, Y., Saadat, M., and Kikuchi, K. (1994) Selective increases in isoform PP1 α of type-1 protein phosphatase in ascites hepatoma cells. *Jpn. J. Cancer Res.* **85**, 274-278
 15. Saadat, M., Mizuno, Y., Takizawa, N., Kakinoki, Y., and Kikuchi, K. (1995) Neoplastic alterations in subcellular distribution of type 1 α protein phosphatase in rat ascites hepatoma cells. *Cancer Lett.* **94**, 165-170
 16. Dent, P., MacDougall, L.K., MacKintosh, C., Campbell, D.G., and Cohen, P.A. (1992) Myofibrillar protein phosphatase from rabbit skeletal muscle contains the β isoform of protein phosphatase-1 complexed to a regulatory subunit which greatly enhances the dephosphorylation of myosin. *Eur. J. Biochem.* **210**, 1037-1044
 17. Hedman, H. and Lundgren, E. (1992) Regulation of LFA-1 avidity in human cells. Requirements for dephosphorylation events for high avidity ICAM-1. *J. Immunol.* **149**, 2295-2299
 18. Ichikawa, K., Hirano, K., Ito, M., Tanaka, J., Nakano, T., and Hartshorne, D.J. (1996) Interactions and properties of the smooth muscle myosin phosphatase. *Biochemistry* **35**, 6313-6320
 19. Kimura, K., Ito, M., Amano, M., Chihara, K., Futaka, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* **273**, 245-248
 20. Helps, N.R., Street, A.J., Elledge, S.J., and Cohen, P.T.W. (1994) Cloning of the complete coding region for human protein phosphatase inhibitor-2 using the two hybrid system and expression of inhibitor 2 in *E. coli*. *FEBS Lett.* **340**, 93-98
 21. Gruppiso, P.A., Johnson, G.L., Constantinides, M., and Brautigan, D.L. (1985) Phosphorylase phosphatase regulatory subunit: "Western" blotting with immunoglobulins against inhibitor-2 reveals a protein of $M_r=60,000$. *J. Biol. Chem.* **260**, 4288-4294
 22. Alessi, D., MacDougall, L.K., Sola, M.M., Ikebe, M., and Cohen, P. (1992) The control of protein phosphatase-1 by targeting subunits: The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. *Eur. J. Biochem.* **210**, 1023-1035
 23. Shimizu, H., Ito, M., Miyahara, M., Ichikawa, K., Okubo, S., Konishi, T., Naka, M., Tanaka, T., Hirano, K., Hartshorne, D.J., and Nakano, T. (1994) Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. *J. Biol. Chem.* **269**, 30407-30411
 24. MacDougall, L.K., Campbell, D.G., Hubbard, M.J., and Cohen, P. (1989) Partial structure and hormonal regulation of rabbit liver inhibitor-1; distribution of inhibitor-1 and inhibitor-2 in rabbit and rat tissues. *Biochim. Biophys. Acta* **1010**, 218-226
 25. Huber, C., Sundstrom, C., Nilsson, K., and Wigzell, H. (1976) Surface receptors on human hematopoietic cell lines. *Clin. Exp. Immunol.* **25**, 367-376
 26. Saiki, O. and Ralph, P. (1983) Clonal efferances in response to T cell replacing factor (TRF) for IgM secretion and TRF receptors in a human B lymphoblast cell line. *Eur. J. Immunol.* **13**, 31-34
 27. Muraguchi, A., Kishimoto, T., Miki, Y., Kuritani, T., Kaieda, T., Yoshizaki, K., and Yamamura, Y. (1981) T cell-replacing factor-(TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. *J. Immunol.* **127**, 412-416
 28. Warner, N.L., Harris, A.W., and Gutman, G.A. (1975) Membrane immunoglobulin and Fc receptors of murine T and B cell lymphomas in *Membrane Receptors of Lymphocytes* (Seligmann, M., Preud'homme, J.L., and Kounilsky, F.M., eds.) pp. 203-216, North-Holland, Amsterdam
 29. Krolick, K.A., Isakson, P.C., Uhr, J.W., and Vitetta, E.S. (1979) BCL1, a murine model for lymphocytic leukemia: Use of the surface immunoglobulin ideotype for the detection and treatment of tumor. *Immunol. Rev.* **48**, 81-106
 30. Kim, K.J., Kanellopoulos-Langevin, C., Merwin, R.M., Sachs, D.H., and Asofsky, R. (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. *J. Immunol.* **122**, 549-554
 31. Cohen, P., Klumpp, S., and Schelling, D.L. (1989) An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. *FEBS Lett.* **250**, 596-600
 32. Burrows, P.D. and Cooper, M.D. (1990) Regulated expression of cell surface antigens during B cell development. *Semin. Immunol.* **2**, 189-195
 33. Gronowicz, E.S., Doss, C.A., Howard, F.D., Morrison, D.C., and Strober, S. (1980) An *in vitro* line of B cell tumor BCL1 can be activated by LPS to secrete IgM. *J. Immunol.* **125**, 976-980
 34. Goldstein, H., Koerholz, D., Chesky, L., Fan, X.D., and Ambrus, Jr., J.L. (1990) Divergent activities of protein kinases in IL-6-induced differentiation of a human B cell line. *J. Immunol.* **145**, 952-961
 35. Raynal, M.C., Liu, Z., Hirano, T., Mayer, L., Kishimoto, T., and Chen-Kiang, S. (1989) Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. *Proc. Natl. Acad. Sci. USA* **86**, 8024-8028
 36. Yano, Y., Sakon, M., Kambayashi, J., Kawasaki, T., Senda, T., Tanaka, K., Yamada, F., and Shibata, N. (1995) Cytoskeletal reorganization of human platelets induced by the protein phosphatase 1/2A inhibitors okadaic acid and calyculin A. *Biochem. J.* **307**, 439-449
 37. Dustin, M.L. and Springer, T.A. (1989) T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. *Nature* **341**, 619-624
 38. Tominaga, T., Sugie, K., Hirata, M., Morii, N., Fukata, J., Uchida, A., Imura, H., and Narumiya, S. (1993) Inhibition of PMA-induced, LFA-1-dependent lymphocyte aggregation by ADP ribosylation of the small molecular weight GTP binding protein, rho. *J. Cell. Biol.* **120**, 1529-1537
 39. Kitazawa, T., Gaylinn, B.D., Denney, G.H., and Somlyo, A.P. (1991) G-protein-mediated Ca²⁺ sensitization of smooth muscle concentration through myosin light chain phosphorylation. *J. Biol. Chem.* **266**, 1708-1715
 40. Aktories, K., Weller, U., and Chatwal, G.S. (1987) *Clostridium botulinum* type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. *FEBS Lett.* **212**, 109-113
 41. Kikuchi, A., Yamamoto, K., Fujita, T., and Takai, Y. (1988) ADP-ribosylation of the bovine brain rho protein by botulinum toxin type C1. *J. Biol. Chem.* **263**, 16303-16308
 42. Morii, N., Teru-uchi, T., Tonegawa, T., Kumagai, N., Kozaki, S., Uchikubi, F., and Narumiya, S. (1992) A rho gene product in human blood platelets. Effect of the ADP-ribosylation by botulinum C3 ADP-ribosyltransferase on platelet aggregation. *J. Biol. Chem.* **267**, 20921-20926
 43. Noda, M., Yasuda-Fukazawa, C., Moriishi, K., Kato, T., Okuda, T., Kurokawa, K., and Takuwa, Y. (1995) Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. *FEBS Lett.* **367**, 246-250